Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemoCentryx, a clinical-stage biopharmaceutical company, has initiated a Phase I clinical trial of CCX025, the company's fourth investigational new drug and second orally administered compound that inhibits the chemokine receptor known as CCR9.
Subscribe to our email newsletter
The Phase I double-blind, placebo-controlled trial of CCX025 is being conducted in healthy male and female volunteers to evaluate the safety, tolerability and pharmacokinetics of CCX025 over a range of dose levels.
In preclinical studies, the compound has been shown to be well-tolerated and highly selective. Like Traficet-EN, CCX025 is differentiated from existing inflammatory bowel disease therapies such as biologics, steroids and immunosuppressives and may offer a novel, safe and conveniently administered treatment option.
Structurally distinct from Traficet-EN, CCX025 is said to strengthen ChemoCentryx’s position in the CCR9 arena and expand the company’s gastrointestinal franchise with the potential to pursue different clinical indications with discrete compounds.
Thomas Schall, president and CEO of ChemoCentryx, said: “With the advancement of CCX025 into the clinic, ChemoCentryx can pursue a greater breadth of diseases associated with CCR9 receptor inhibition with the clear advantage of having two structurally distinct, very potent and highly-selective oral therapeutics.”